About This EventSionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing ...
Jennifer Fitzpatrick, directrice juridique de Sionna Therapeutics, a vendu le 5 décembre 2025 un total de 10 250 actions de ...
Bridgehouse Asset Managers (Bridgehouse) today announced management fee reductions for the Brandes Emerging Markets Value Fund and the Brandes International Equity Fund.
28/11 Un administrateur de Sionna Therapeutics cède des actions pour 4,8 millions de dollars, selon un dépôt auprès de la SEC MT 19/11 SIONNA THERAPEUTICS, INC. : Opinion positive de BTIG ZM 05/11 ...
Investing.com - RBC Capital downgraded Sionna Therapeutics (NASDAQ:SION) from Sector Perform to Underperform on Monday, maintaining a price target of $24.00. The downgrade comes after SION shares ...
As of Monday, December 01, Sionna Therapeutics, Inc.’s SION share price has dipped by 11.58%, which has investors questioning if this is right time to buy.
Investing.com -- Sionna Therapeutics (NASDAQ:SION) stock tumbled 16% after RBC Capital downgraded the cystic fibrosis drug developer to Underperform from Sector Perform, while maintaining a $24 price ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Building on this, Sionna has initiated a Phase 2a proof-of-concept trial for SION-719 in combination with the standard cystic fibrosis treatment, Trikafta. Analyst coverage has been active, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback